Clinical Research Directory
Browse clinical research sites, groups, and studies.
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Sponsor: Hadassah Medical Organization
Summary
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2008-07
Completion Date
2027-01
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
Autologous or Allogeneic tumor cells
Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
Locations (1)
Hadassah Medical Organization
Jerusalem, Israel